Buscador de noticias

Job Verdonschot, Maastricht University Medical Center, and the Cardiovascular Research Institute Maastricht

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

Scientist at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Institute for Research in Biomedicine (IRB Barcelona) uncover a key metabolic mechanism governing immune cell readiness

TARGET-DC, CNIC initiative led by Dr. David Sancho aims to identify novel immune checkpoints in dendritic cells to advance T-cell activation.

The initiative will combine innovative medical and digital technologies to improve the early detection of cardiac risk and complications in cancer patients and survivors 

The Young Author Achievement Award recognises her research into cardiotoxicity published in JACC: Cardio-Oncology